Phathom Pharmaceuticals (PHAT) Operating Leases (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Operating Leases data on file, last reported at $2.0 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $2.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (changed N/A YoY), and the FY2025 annual result was $2.1 million, changed N/A from the prior year.
• Operating Leases declined to $2.0 million in Q1 2026 per PHAT's latest filing, from $2.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $2.1 million in Q3 2025 and troughed at $133000.0 in Q2 2024.
• A 5-year average of $1.1 million and a median of $1.0 million in 2022 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2025: Operating Leases tumbled 83.14% in 2024, then jumped 342.86% in 2025.
• A 5-year view of Operating Leases shows it stood at $1.1 million in 2022, then sank by 57.92% to $462000.0 in 2023, then sank by 71.21% to $133000.0 in 2024, then soared by 1452.63% to $2.1 million in 2025, then slipped by 5.04% to $2.0 million in 2026.
• Business Quant data shows PHAT's Operating Leases at $2.0 million in Q1 2026, $2.1 million in Q4 2025, and $2.1 million in Q3 2025.